Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.
Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM). Márquez-Rodas I, et al. Among authors: cerezuela p. PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015. PLoS One. 2015. PMID: 25874698 Free PMC article.
Advances in cutaneous melanoma.
Espinosa E, Berrocal A, López Martín JA, González Cao M, Cerezuela P, Mayordomo JI, Martín Algarra S; Grupo Español de Melanoma (GEM). Espinosa E, et al. Among authors: cerezuela p. Clin Transl Oncol. 2012 May;14(5):325-32. doi: 10.1007/s12094-012-0804-4. Clin Transl Oncol. 2012. PMID: 22551537 Review.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Márquez-Rodas I, et al. Among authors: cerezuela p. Ann Transl Med. 2015 Oct;3(18):267. doi: 10.3978/j.issn.2305-5839.2015.10.27. Ann Transl Med. 2015. PMID: 26605313 Free PMC article. Review.
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S. Espinosa E, et al. Among authors: cerezuela p. Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254. Melanoma Res. 2016. PMID: 26958991 Free PMC article.
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: cerezuela p. J Immunother Cancer. 2021 Mar;9(3):e001664. doi: 10.1136/jitc-2020-001664. J Immunother Cancer. 2021. PMID: 33782108 Free PMC article. Review.
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Gonzalez-Cao M, et al. Among authors: cerezuela p. Nat Commun. 2021 Dec 1;12(1):7008. doi: 10.1038/s41467-021-26572-6. Nat Commun. 2021. PMID: 34853302 Free PMC article. Clinical Trial.
Access to melanoma drugs in Spain: a cross-sectional survey.
Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MÁ, Cerezuela P, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: cerezuela p. Clin Transl Oncol. 2024 Oct;26(10):2572-2583. doi: 10.1007/s12094-024-03501-9. Epub 2024 May 16. Clin Transl Oncol. 2024. PMID: 38750345
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J. Almenar D, et al. Among authors: cerezuela p. Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8. Eur J Cancer Care (Engl). 2009. PMID: 19076208 Free PMC article.
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
Gonzalez-Billalabeitia E, Castellano D, Sobrevilla N, Guma J, Hervas D, Luengo MI, Aparicio J, Sanchez-Muñoz A, Mellado B, Saenz A, Valverde C, Fernandez A, Margeli M, Duran I, Fernandez S, Sastre J, Ros S, Maroto P, Manneh R, Cerezuela P, Carmona-Bayonas A, Ayala de la Peña F, Luis Aguilar J, Rivera S, García Del Muro X, Germà-Lluch JR; Spanish Germ Cell Cancer Group/Grupo Germinal (SGCCG). Gonzalez-Billalabeitia E, et al. Among authors: cerezuela p. J Natl Cancer Inst. 2017 Jan 25;109(4). doi: 10.1093/jnci/djw265. Print 2017 Jan. J Natl Cancer Inst. 2017. PMID: 28122896
15 results